Safety Evaluation of 3K3A-APC in Ischemic Stroke

PHASE2CompletedINTERVENTIONAL
Enrollment

110

Participants

Timeline

Start Date

October 31, 2014

Primary Completion Date

April 18, 2017

Study Completion Date

June 29, 2017

Conditions
Ischemic Stroke
Interventions
BIOLOGICAL

3K3A-APC

3K3A-APC, diluted in 0.9% sodium chloride in water, given as 100 mL IV infusion

DRUG

Placebo

Matching placebo, 0.9% sodium chloride in water, given as 100 mL IV infusion

Trial Locations (15)

10032

Stroke Center, New York

14209

Stroke Center, Buffalo

14642

Stroke Center, Rochester

15213

Stroke Center, Pittsburgh

22904

Stroke Center, Charlottesville

37232

Stroke Center, Nashville

43210

Stroke Center, Columbus

45208

Stroke Center, Cincinnati

60611

Stroke Center, Chicago

63110

Stroke Center, St Louis

66160

Stroke Center, Kansas City

75390

Stroke Center, Dallas

84132

Stroke Center, Salt Lake City

90048

Stroke Center, Los Angeles

02114

Stroke Center, Boston

All Listed Sponsors
collaborator

National Institute of Neurological Disorders and Stroke (NINDS)

NIH

collaborator

Cedars-Sinai Medical Center

OTHER

collaborator

Massachusetts General Hospital

OTHER

collaborator

University of Iowa

OTHER

lead

ZZ Biotech, LLC

INDUSTRY

NCT02222714 - Safety Evaluation of 3K3A-APC in Ischemic Stroke | Biotech Hunter | Biotech Hunter